Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100 000 patients in randomized trials

Circulation

Volumn 97, Issue 22, 1998, Pages 2202-2212

  Franzosi, Maria Grazia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

ACE inhibitors; Myocardial infarction; Systematic overview; Trials

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOLYTIC AGENT; LISINOPRIL;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDICATION; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART RATE; HIGH RISK POPULATION; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 0032499670     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.22.2202     Document Type: Article

References (33)

1. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. on behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678-684.
2. Gruppo Italians per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisínopríl and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet, 1994;343:1115-1122.
3. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-685.
4. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13.634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1), Lancet. 1995;345:686-687.
5. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80-85.
6. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-677.
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
8. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbek J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm A, for the Trandolapril Cardíac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
9. Latíni R, Maggioni AP, Father M, Sleight P, Tognoni G, for the meeting participants. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation. 1995;92:3132-3137.
10. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-1456.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categoríes of patients. BMJ. 1994;308:80-106.
12. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction; collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
13. Latini R, Avanzini F, De Nicolao A, Rocchetti M, and the GISSI-3 Investigators. Effects of lisinopril and nitroglycerin on blood pressure early after myocardial infarction: the GISSI-3 pilot study. Clin Pharmacol Ther. 1994;56:680-692.
14. Flalher M, Pipilis A, Collins R, Budaj A, Hargreaves A, Kolettis T, Jacob A, Millane T, Fitzgerald L, Cedro K. Randomised controlled trial of oral captopril, of oral isosorbide mononitrate and of intravenous magnesium sulphate started early in acute myocardial infarction: safety and haemodynamic effects. Ear Heart J. 1994;15:608-619.
15. Kingma JH, van Gilst WH, Peels CH, Dambrink J-HE, Verheught FWA, Wielenga RP, for the CATS Investigators. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction: results from the Captopril And Thrombolysis Study (CATS). Ear Heart J. 1994;15:898-907.
16. Nabel EG, Topol EJ, Galeana A, Ellis SG, Bates ER, Werns SW, Walton JA, Muller DW, Schwaiger M, Pin B. A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction. J Am Coll Cardiol. 1991;17:467-473.
17. Foy SG, Crazier IG, Turner JO, Richards AM, Frampton CM, Nicholls MG, Ikram H. Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the 'PRACTICAL' Study). Am J Cardiol. 1994;73:1180-1186.
18. Galcera-Tomas J, Nuno de la Rosa JA, Torres-Martinez G, Rodriguez-Garcia P, Castillo-Soria FJ, Canton-.Martinez A, Campos-Peris JV, Pico-Aracil F, Ruiz-Ros JA, Ruiperez-Abizanda JA. Effect of early use of captopril on haemodynamics and short-term ventricular remodelling in acute anterior myocardial infarction. Eur Heart J. 1993;14:259-266.
19. Hargreaves AD, Kolettis T, Jacob AJ, Flint LL, Turnbull LW, Muir AL, Boon NA. Early vasodilator treatment in myocardial infarction: appropriate for the majority or minority? Br Heart J. 1992;68:369-373.
20. Hochrnan JS, Srichai MB, Picard M. Palmeri S, Deutsch E, Edelstein R, Sands M, Sonnenblick E, LeJemtel T, for the CAPTIN Investigators. Very early ACE inhibition reduces progressive left ventricular dilation when tPA fails to establish early reperfusion during acute anterior myocardiai infarction. Circulation. 1994;90(suppl I):1-19. Abstract.
21. Ray SG, Pye M, Oldroyd KG, Christie J, Connelly DT, Northridge DB, Ford I, Morton JJ Dargie HJ, Cobbe SM. Early treatment with captopril after acute myocardial infarction, Br Heart J. 1993;69:215-222.
22. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting enzyme inhibition. Lancet. 1991;337:872-876.
23. Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction, Lancet. 1988;1:255-259.
24. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction, N Engl J Med. 1988;319:80-86.
25. The SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
26. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventrícular ejection fractions. N Engl J Med. 1992;327:685-691.
27. Stewart LA, Clarke MJ. Practical methodology of meta-analyse (overviews) using updated individual patient data. Stat Med, J 2057-2079.
28. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
29. Efron B, Morris C, Stein's paradox in statistics. Sci Am. 1977;236: 119-127.
30. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: analysis and examples. Br J Cancer. 1977;35:1-39.
31. Kjekshus J, Swedberg K, for the CONSENSUS II Study Group Importance of first dose hypotension with enalaprilat in acute myocardiol infarction. J Am Coll Cardiol, 1992;19:206. Abstract.
32. Bonaduce D, Marciano F, Petretta M, Migaux ML, Morgano G, Bianchi V, Salemme L, Valva G, Condorelli M. Effects of converting enzyme inhibition on heart period variability in patients with acute myocardial infarction. Circulation. 1994;90:108-113.
33. Van Gilst WH, Kingma JH, Peels KH, Dambrink JE, St John Sutton M, on behalf of the CATS Investigators. Which patient benefits from early angíotensin-converting enzyme inhibítíon after myocardial infarction? Results of one-year seríal echocardìographíc follow-up from the Captopril and Thrombolysis Study (CATS), J Am Coll Cardiol. 1996;28:114-121.